PATENT CLAIM ANALYSIS

Application Number: 15866109
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-11
Patent Classification: ["514", "020800"]

Abstract:
Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.

Claim (Index 37):
The method of  claim 21 , wherein the peptide is modified to prevent the peptide from crossing the blood-ocular barrier when administered to the subject.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 86.0
- Lexical Diversity: 1.70588
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15113035', '14878370', '14240132', '15676968', '15611025']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7286315302010224
- 35 USC 102 Novelty (BERT): 0.605249160121858
- Combined Prediction Score: 0.716293293193106
- Mean Citation Score: 301.996302
- Max Citation Score: 521.884
- Similarity Product: 462.0249216179848

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test